Mablink Bioscience to be acquired by Lilly
Mablink Bioscience, a pre-clinical company pioneering the development of next-generation antibody-drug conjugates via its PSARLinkTM proprietary platform, announced an agreement to be acquired by Eli Lilly and Company. The transaction is subject to approval from the French Ministry of the Economy.
Lenz & Staehelin advises Lilly in this transaction. The team includes Tino Gaberthüel (partner, M&A), Xavier Grivel (associate, M&A) and Martin Aebi (counsel, IP/litigation).